SEC Filing Summary: Pro-Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Pro-Pharmaceuticals, Inc. on February 15, 2002. The filing discloses a change in the company's independent certifying accountants. Note: The request metadata references "GALECTIN THERAPEUTICS INC," but the filing text explicitly identifies the registrant as "PRO-PHARMACEUTICALS, INC."
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on the administrative change of auditors.
Material Changes
- Dismissal of Auditor: On February 15, 2002, management dismissed Scillia Dowling & Natarelli LLC as independent auditors.
- Engagement of New Auditor: On February 22, 2002, Deloitte & Touche LLP was engaged to audit financial statements for the fiscal year ended December 31, 2001.
- Approval: The Board of Directors and Audit Committee approved the change.
Management Commentary, Risks, and Contingencies
Management stated that the reports issued by the former auditor (Scillia Dowling & Natarelli LLC) for the period ending December 31, 2000, and the interim periods of 2001, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, scope, or accounting principles.
From March 31, 2001, through February 15, 2002, there were no disagreements between the company and the former auditor on accounting principles, financial statement disclosures, or auditing scope/procedures.
The company confirmed it did not consult with the new auditor (Deloitte & Touche LLP) regarding accounting applications, potential audit opinions, or reportable events prior to engagement.
Investor Verification Checklist
- Verify the attached letter from Scillia Dowling & Natarelli LLC (Exhibit 16) to confirm they agree with the company's statements regarding the dismissal.
- Confirm the effective date of the new audit engagement with Deloitte & Touche LLP for the 2001 fiscal year.
- Review subsequent filings to ensure the new auditor issues an unqualified opinion on the 2001 financial statements.
- Clarify the relationship between "Pro-Pharmaceuticals, Inc." and "Galectin Therapeutics Inc." given the discrepancy in the request metadata.